Marketing a CRO, Biotech, or Medtech to Buyers Who Don't Read Marketing Content

What you'll take away

• Why the researcher, the medical director, and the Value Analysis Committee member are structurally allergic to marketing content, and what they read instead
• The 5-to-16-person buying committee that will decide your deal, and who is actually on it
• The specific formats that get into a Value Analysis Committee packet, and the ones that get deleted from the inbox
• Why lead velocity is the wrong metric for a 12-to-18-month cycle, and what to measure instead
• A one-week reset for your top of funnel that trades the polished datasheet for the thing your buyer actually cites

I've spent the last decade helping scientific and healthcare clients turn research into content their buyers will actually use. The lesson that took the longest to learn: your buyer is not "the healthcare market." Your buyer is a scientist, a medical director, or a hospital Value Analysis Committee member, and they read almost nothing that looks like marketing.

They read protocols. They read peer-reviewed studies. They read datasheets, when the datasheet is a real datasheet and not twelve pages of glossy claim without a method section. They read what their colleagues send them. They read what the Value Analysis Committee packet includes. And they read whatever the vendor's technical documentation says, because that is the document the implementation team will inherit.

If your top of funnel is a whitepaper landing page with a gated PDF titled "The Complete Guide to Transforming Precision Medicine," the buyer already skipped it. Not out of malice. Because that title tells them there is nothing in it.

Who is actually in the room

Enterprise B2B buying groups now range from 5 to 16 people, and 74% of them report unhealthy conflict during the decision process (Gartner Sales Survey, May 2025). In healthcare, life sciences, and medtech, that room typically has a version of the following people, and each one reads a different document.

The clinical decision-maker. A medical director, a chief of a service line, a principal investigator, a lead researcher. They read the methodology, the protocol, the published study, the safety data. They do not care about your brand story. They care whether the science supports the claim.

The financial stakeholder. A CFO or a finance director. They read the pricing, the total cost of ownership, the reimbursement pathway (if applicable), and the utilization projections. They will forgive a rough deck. They will not forgive a missing pricing model.

The operational buyer. A hospital administrator, a lab manager, a practice administrator, a director of operations. They read the implementation plan, the training requirements, the staff time impact, the workflow diagrams. If you can't tell them how many hours per week their team will spend on your product for the first 90 days, they will assume the answer is "a lot" and move on.

The regulatory or compliance stakeholder. A compliance officer, a regulatory affairs lead. They read the FDA clearance, the accreditation status, the audit history, the specific privacy and security posture. In a hospital purchase, this person can veto without explaining why.

The end user. A clinician, a technician, a lab scientist. They read the user manual, if there is one. They ask their colleagues in a Slack group or on a professional listserv whether anyone else uses the product.

The champion. The person inside the account who wants your product. They are the only one in the room who reads your marketing content. Everything you give them is a resource for the conversations they will have with the other 4 to 15 people.

The champion is the one you're actually writing for. Not to convince them (they're already convinced) but to arm them.

What they read instead of your marketing content

Life science marketers surveyed in 2025 report a shift: gated whitepapers are being replaced by ungated, buyer-centric technical content, and 73% of B2B life-science marketers now incorporate content marketing into their digital strategy (INFUSE Evolving Role of Content Marketing in Life Science 2025; L7 Creative Life Sciences Content Marketing 2025). Meanwhile, 81% of B2B buyers choose their preferred vendor before speaking to sales (Whitehat life sciences summary of Forrester data).

What that means in practice: your buyer built their shortlist before you ever spoke to them. The content that got you on the shortlist was not your homepage hero. It was one of these:

• A peer-reviewed publication in a journal your buyer's specialty reads
• A protocol or methods document published on your site, ungated, with real detail
• A case study written in the language of the specialty, with the specific institution, the specific method, the specific outcome, and the specific limitations
• A published comparison table that includes your product's honest weaknesses next to competitors' honest strengths
• A technical documentation library that the implementation team can read before they buy
• A conference poster or presentation the buyer or their colleague attended
• A recommendation from a colleague on a professional Slack, listserv, or in-person meeting

Every one of those artifacts is a marketing asset. None of them look like marketing.

The Value Analysis Committee packet

For medical device and hospital purchase decisions, the Value Analysis Committee (call it the VAC, the hospital committee that evaluates whether a product should be approved for use before purchase) is the room where the deal lives or dies. VAC workflows follow a defined multi-stage process: product request submission, clinical and financial evaluation, sometimes a trial or pilot, then a formal approval or rejection (Provyx Value Analysis Committee Guide for Device Vendors; CASRAI Value Analysis Committee guide).

The champion in the account is the person who submits the VAC request. Their packet includes:

• A completed VAC form
• Published clinical evidence supporting the request
• Financial analysis: acquisition cost, ongoing cost, utilization forecast
• Comparison to alternatives, including the status quo
• Safety and quality data
• Implementation and training plan
• References from peer institutions

Your job as the vendor is to make every one of those documents easy for the champion to assemble. If your published clinical evidence is on a page behind a form fill and a sales-team follow-up, the champion is going to use someone else's evidence. If your financial analysis lives in a proposal that requires three calls to get, the champion is going to build their own from public list prices and get it wrong.

The champion's packet is your marketing top of funnel, whether you designed it that way or not. Every asset you publish should be structured so that a copy-and-paste into a VAC packet is a two-minute exercise, not a two-week project.

The datasheet trap

The single most common failure I see in life-science marketing content: the twelve-page datasheet. Cover, glossy product shot, brand story, three pages of claims with no method section, a comparison table with all-green checkmarks in your column, and the actual technical specifications on page eleven in six-point type.

Nobody in the buying committee will read that document past page two. The clinical decision-maker will look for the method section and not find it. The financial stakeholder will look for pricing and not find it. The operational buyer will look for implementation and not find it. The compliance stakeholder will look for the FDA clearance details and not find it. The end user will look for the user experience and not find it.

The document was designed to look impressive. Its buyers wanted it to be useful.

The replacement is not shorter. It is honest. Two pages of real specifications, with methodology, with real trade-offs, with real limits, with real reference customers. If your product is genuinely better than the alternative, that document will show it. If it isn't, the twelve-page glossy one wasn't fooling anyone anyway.

Why lead velocity is the wrong metric

Biotech sales cycles average 12 to 18 months because of regulatory requirements and multi-stakeholder decision dynamics (Apollo Biotech Sales Market Guide). Enterprise medical software runs 12 months or more (Martal Medical Software Sales Cycle 2025).

At 12 to 18 months, a lead generated in September may not appear in the pipeline as an opportunity until May, may not enter the VAC review until August, and may not close until the following January. Reporting "leads generated per month" in isolation gives you no signal about whether the marketing is working. Every lead is being judged before it has had a chance to convert.

The metrics that do give you a signal on a long cycle:

• Champion identification per account. How many named champions have you developed inside target accounts in the last quarter? These are the people who will submit VAC requests. If the number is zero, marketing is not doing its job regardless of lead volume.
• VAC packet assembly time in target accounts. How long does it take a champion to assemble a complete packet using your published materials? If it's more than a week, your top of funnel is not structured for the buyer.
• Time-in-stage by pipeline stage. How long does a deal sit in each stage before moving? Long stalls are the marketing signal, not slow lead velocity.
• Meeting acceptance rate from champion accounts. Champions who trust the material will get you meetings with the rest of the committee.
• Cost of acquiring a customer paid back, on your actual cycle. For a 12-month cycle, the honest read on cost of customer acquisition paid back happens no earlier than month 18. Before that, you have leading indicators only.

If your board is asking about lead velocity every 90 days on a 12-to-18-month sales cycle, they are asking about the wrong number. The two-clock rule from our earlier field note (leading indicators every 30 days, lagging indicators at 6 and 12 months) applies here as strictly as it does in general B2B.

A one-week reset

If you're running a CRO, biotech, or medtech marketing program right now and any of this hit, here's what to do this week:

1. Open your top three "high-performing" marketing pieces. Read the first two pages of each one as if you were a medical director. Note every claim without a method or a citation.
2. Ungate the two pieces that have the most real technical content and the most defensible claims. Republish them at stable URLs.
3. For each ungated piece, add a "cite this in a VAC packet" section at the top: the recommended sentence, the reference, the link, the two sentences your champion should paste into their packet.
4. Kill the twelve-page datasheet. Replace it with a two-page technical spec sheet and a separate one-page methods and limitations sheet.
5. In the CRM, add a field to every target account called "identified champion." Track it. Champion count is the number that matters.

The reset takes one week. The marketing motion it enables takes 12 to 18 months to fully show up in revenue. That is the actual timeline.

The honest limit

Some products are genuinely not ready for the VAC packet. If your clinical evidence is thin, if your FDA path is unclear, if your safety data has holes, no packet rewrite will save you. In that case, the honest work is with the science team and the regulatory team before it's with the marketing team.

The rest of the time, the buyer is out there, they are reading, and they are choosing preferred vendors before you speak to them. Your marketing job is to be the vendor whose materials they can actually use.

If you're the founder, COO, or head of marketing at a CRO, biotech, medtech, or healthcare-adjacent SaaS company and your best asset is a twelve-page datasheet with a brand story on the cover, [book a pipeline call](https://isovertic.com/book) and send us the top of funnel piece you're currently proudest of. In about ten minutes I'll tell you whether it survives a VAC packet, which two pages your champion would keep, and what to publish instead. Sometimes the honest answer is that you're already fine, and we're happy to say so and hand you back your afternoon.